Page 137 - CW E-Magazine (23-4-2024)

Pharmaceuticals Pharmaceuticals

LEADERSHIP CHANGE RELIEF FOR COMPANIES
Dhananjay Singh is new MD of Merck Life Science Prices of APIs from China see a sharp fall: Report

German science and technology for driving the life science strategy “Merck Life Science is committed Prices of Active Pharmaceutical Ingre- The demand for APIs has gone down, PAP (p-Aminophenol) for paracetamol
major, Merck, has appointed in India, ensuring governance and to meeting our customers’ demands dients (API) are seeing the biggest- too,” said Mr. Mehul Shah, who tracks the and there have also been instances of
Mr. Dhananjay Singh as Managing compliance alongside other leaders through our strategic focus on “India ever drop after COVID-19, according to a Chinese pharmaceutical industry. While carry-forward stocks of APIs and inter-
Director of Merck Life Science, in India. from Merck’s businesses in India. for India and India for the Globe”, report in the Economic Times. The pharma China scaled up signifi cantly, the demand mediates for the last one year.
He has taken over from Mr. Sreenath Mr. Singh’s appointment is in addi- aligned with our country strategy, industry is said to be reporting a 50% for APIs has gone down as India has taken
N. S., who retired after 36 years with tion to his current role as Head of our strong partnerships with valued retreat in API costs. The trend, industry steps to become self reliant, according to “Very importantly, there has been
Merck in the country. In his role as Science and Lab Solutions Commercial customers and our dedicated team,” experts say will result in high operating industry observers. overcapacity in the hope of higher
the MD, Mr. Singh will be responsible (India). Mr. Singh said, in a statement. profi t margins of companies in the next demand. On the contrary, there has been
two-three quarters. Mr. Dinesh Dua, former Chairman a demand compression. All of these four
COLLABORATION of Pharmaceutical Export Promotion factors in order of priority have made
industry,
India’s
Council (Pharmexcil), said there are all the difference in terms of a drop in
Dr. Reddy’s, Bayer ink pact for second brand of Vericiguat which is dependent on China for APIs, several factors that led to the pronounced the prices of Chinese APIs and inter-
pharmaceutical
intermediates and bulk drugs, had seen price decline. “There are various factors, mediates,” he said.
Dr. Reddy’s Laboratories and Bayer medical therapy, in adults with symp- the possibilities with this partnership,”
have entered into a partnership to mar- tomatic chronic heart failure with Ms. Shweta Rai, Managing Director, an exponential price increase during including that of the Chinese cartelisation India’s imports of organic chemicals,
COVID times. The rise in API prices being broken in the past six months – both
ket and distribute a second brand of reduced ejection fraction (less than 45 Bayer Zydus Pharma and Country continued until early this year. However, for APIs and intermediates,” he said. which includes APIs, rose 39% in FY22
Vericiguat in India. percent), following a recent event of Division Head (CDH) for Bayer’s things have started to change, the report from a year earlier to $12.5-bn, refl ect-
worsening heart failure which required Pharmaceuticals Business in South
Under the terms of this agreement, hospitalisation or outpatient intra- Asia said in a press release. noted. “Prices have seen a sharp decrease Mr. Dua said India has also become ing the reliance on key inputs that go into
Bayer has granted non-exclusive rights venous (IV) diuretics. in the last two months. self-suffi cient in some intermediates like making medicines.
to Hyderabad-based Dr. Reddy’s under Vericiguat works on a pathway PRODUCT QUALITY
the brand name Gantra. “Despite therapy, chronic heart not currently targeted by existing heart
failure patients can experience dis- failure treatments and can reduce the Glenmark recalls over 6,000 bottles of blood
Vericiguat, a soluble guanylate ease progression that disrupts their combined risk of cardiovascular death
cyclase (sGC) stimulator in India, is lives and leads to worsening heart and heart failure hospitalisation in such pressure drug in US
indicated, along with guideline-based failure events. We are excited about patients, the release noted.
Glenmark Pharmaceuticals is Hydrochloride extended-release capsules, initiated the ‘Class II recall’ of the drug
PY Genrone Intermediates opens pilot plant in Gujarat recalling 6,528 bottles of a medication the US Food and Drug Administration across the US on March 26. As per the
USFDA, a ‘Class II recall’ is initiated in
used to treat high blood pressure in the said in its latest Enforcement Report.
Gujarat-based speciality chemicals The company said the pilot plant management therapeutic segment,” the American market due to failed dissolution a situation in which the use of, or expo-
company, PY Genrone Intermediates will focus on “validating its production company informed. specifi cations, the US health regulator The affected lot has been produced sure to, a violative product may cause
Pvt. Ltd., has informed about the open- processes/technologies and scaling up said. in India and is being recalled by New temporary or medically reversible
ing of its new pilot plant in Gujarat. the manufacturing process from R&D The facility has provision for future Jersey-based Glenmark Pharmaceuti- adverse health consequences or where
The facility will also double up as a scale to a feasible level”. “Currently we expansion, with space available to The US-based arm of the fi rm is cals Inc. for “failed dissolution speci- the probability of serious adverse health
kilo-scale plant capable of producing will be validating the three indigenously accommodate a similar sized plant. A recalling the affected lot of Diltiazem fi cations”, the USFDA said. Glenmark consequences is remote.
API intermediates at 5-kgs to 50-kgs developed products in our inhouse commercial scale plant is also under Cipla to buy Ivia Beaute’s cosmetics and personal
per batch. R&D lab for cardiovascular and pain construction, the company informed.
care business for Rs. 130-crore
Lupin launches generic bacterial pneumonia drug in US
Mumbai-based Cipla has announced Bhimsaini on a worldwide basis, for consumer of India. The growing adoption
Lupin has announced the launch is indicated for the treatment of only bacterial pneumonia, acne, chlamydia that its consumer healthcare arm, Cipla Rs. 130-crore. of beauty and personal care products in
of the fi rst generic version of Oracea infl ammatory lesions (papules and infections, Lyme disease, cholera, Health Ltd. (CHL) has signed a business Indian households signals a prominent
(doxycycline capsules, 40-mg), in pustules) of rosacea in adult patients. typhus, and syphilis. It is also pre- transfer agreement for the purchase of “Building on its strong presence trend, positioning the market as crucial
the US. The launch comes after get- It is a broad-spectrum antibiotic of the scribed to prevent malaria. Doxycycline cosmetics and personal care distribu- through a cluster of brands in Tier 2-6 for CHL’s expansion efforts,” a statement
ting approval from the United States tetracycline class used in the treatment capsules had estimated annual sales of tion and marketing business of Delhi- towns, CHL is strengthening its play in from the company said. It added that the
Food and Drug Administration (US of infections caused by bacteria and $128-mn in the US (as per IQVIA MAT based Ivia Beaute Pvt. Ltd. including the fast-growing beauty and personal acquired brands will complement CHL’s
FDA). Doxycycline capsules, 40-mg, certain parasites. It is indicated to treat February 2024). the latter’s brands Astaberry, Ikin and care sector catering to the aspirational offerings in the skin care segment.

136 Chemical Weekly April 23, 2024 Chemical Weekly April 23, 2024 137

Contents Index to Advertisers Index to Products Advertised